Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2396674
Max Phase: Preclinical
Molecular Formula: C28H32Cl2FN3O3
Molecular Weight: 548.49
Molecule Type: Small molecule
Associated Items:
ID: ALA2396674
Max Phase: Preclinical
Molecular Formula: C28H32Cl2FN3O3
Molecular Weight: 548.49
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)C[C@@H]1N[C@@H](C(=O)N[C@H]2C[C@@](C)(O)C2)[C@H](c2cccc(Cl)c2F)[C@]12C(=O)Nc1cc(Cl)ccc12
Standard InChI: InChI=1S/C28H32Cl2FN3O3/c1-26(2,3)13-20-28(17-9-8-14(29)10-19(17)33-25(28)36)21(16-6-5-7-18(30)22(16)31)23(34-20)24(35)32-15-11-27(4,37)12-15/h5-10,15,20-21,23,34,37H,11-13H2,1-4H3,(H,32,35)(H,33,36)/t15-,20-,21-,23+,27+,28+/m0/s1
Standard InChI Key: MZBOZBMARIQZGX-GRRGFIRHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: Yes | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 548.49 | Molecular Weight (Monoisotopic): 547.1805 | AlogP: 4.91 | #Rotatable Bonds: 4 |
Polar Surface Area: 90.46 | Molecular Species: BASE | HBA: 4 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.88 | CX Basic pKa: 8.99 | CX LogP: 4.33 | CX LogD: 2.74 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.44 | Np Likeness Score: -0.15 |
1. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S.. (2013) A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice., 56 (13): [PMID:23786219] [10.1021/jm4005708] |
2. Blackburn TJ, Ahmed S, Coxon CR, Liu J, Lu X, Golding BT, Griffin RJ, Hutton C, Newell DR, Ojo S, Watson AF, Zaytzev A, Zhao Y, Lunec J, Hardcastle IR.. (2013) Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and intermediates. Details for the biological evaluation. Further details for the modeling. Table of combustion analysis data. See DOI: 10.1039/c3md00161jClick here for additional data file., 4 (9): [PMID:24078862] [10.1039/c3md00161j] |
3. Aguilar A, Sun W, Liu L, Lu J, McEachern D, Bernard D, Deschamps JR, Wang S.. (2014) Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles., 57 (24): [PMID:25496041] [10.1021/jm501541j] |
4. (2014) Spiro-oxindole MDM2 antagonists, |
5. (2015) Spiro-oxindole MDM2 antagonists, |
6. Hügel HM, de Silva NH, Siddiqui A, Blanch E, Lingham A.. (2021) Natural spirocyclic alkaloids and polyphenols as multi target dementia leads., 43 [PMID:34153839] [10.1016/j.bmc.2021.116270] |
Source(2):